ATARA BIOTHERAPEUTICS, INC.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $630.0K | — | $516.0K | — | — | — | $3.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $1.3M | — | $164.0K | — | — | — | $2.9M |
| SG&A Expense | — | $3.8M | — | $3.6M | — | — | — | $4.0M |
| Operating Income | — | $-4.7M | — | $-3.4M | — | — | — | $-3.6M |
| Operating Margin | — | -749.2% | — | -652.9% | — | — | — | -103.5% |
| Interest Expense | — | $191.0K | — | $830.0K | — | — | — | $909.0K |
| Pretax Income | — | $-4.8M | — | $-4.1M | — | — | — | $-4.3M |
| Income Tax Expense | — | $1.0K | — | $0 | — | — | — | $28.0K |
| Net Income | — | $-4.8M | — | $-4.1M | — | — | — | $-4.3M |
| Net Margin | — | -767.3% | — | -803.3% | — | — | — | -124.6% |
| EPS (Basic) | — | $-0.32 | — | $-0.29 | — | — | — | $-0.32 |
| EPS (Diluted) | — | $-0.32 | — | $-0.29 | — | — | — | $-0.32 |
| Shares Outstanding (Basic) | 10.0M | 15.0M | 9.0M | 14.1M | 8.2M | 7.3M | 7.2M | 13.6M |
| Shares Outstanding (Diluted) | 10.0M | 15.0M | 9.0M | 14.1M | 8.2M | 7.3M | 7.2M | 13.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |